| Trial ID: | L5662 |
| Source ID: | NCT00885352
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00885352/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Sitagliptin|DRUG: Comparator: Placebo|DRUG: Pioglitazone|DRUG: Metformin|DRUG: Glipizide
|
| Outcome Measures: |
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 26, Change from baseline reflects the Week 26 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin., Baseline and Week 26 | Secondary: Change From Baseline in 2-Hour Post-Meal Glucose (PMG) at Week 26, Change from baseline reflects the Week 26 value minus the baseline value., Baseline and Week 26|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26, Change from baseline reflects the Week 26 value minus the baseline value., Baseline and Week 26
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
313
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-04-15
|
| Completion Date: |
2010-11-10
|
| Results First Posted: |
2012-02-01
|
| Last Update Posted: |
2017-05-23
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00885352
|
